| Literature DB >> 27436577 |
Monika Gjorgjieva1,2,3, Margaux Raffin1,2,3, Adeline Duchampt1,2,3, Ariane Perry4, Anne Stefanutti1,2,3, Marie Brevet2,5, Antonin Tortereau2,6, Laurence Dubourg2,3,7,8, Aurélie Hubert-Buron4, Mylène Mabille9,10, Coralie Pelissou9,10, Louis Lassalle9,10, Philippe Labrune4,10, Gilles Mithieux1,2,3, Fabienne Rajas11,2,3.
Abstract
Glycogen storage disease type I (GSDI) is a rare metabolic disease due to glucose-6 phosphatase deficiency, characterized by fasting hypoglycemia. Patients also develop chronic kidney disease whose mechanisms are poorly understood. To decipher the process, we generated mice with a kidney-specific knockout of glucose-6 phosphatase (K.G6pc-/- mice) that exhibited the first signs of GSDI nephropathy after 6 months of G6pc deletion. We studied the natural course of renal deterioration in K.G6pc-/- mice for 18 months and observed the progressive deterioration of renal functions characterized by early tubular dysfunction and a later destruction of the glomerular filtration barrier. After 15 months, K.G6pc-/- mice developed tubular-glomerular fibrosis and podocyte injury, leading to the development of cysts and renal failure. On the basis of these findings, we were able to detect the development of cysts in 7 out of 32 GSDI patients, who developed advanced renal impairment. Of these 7 patients, 3 developed renal failure. In addition, no renal cysts were detected in six patients who showed early renal impairment. In conclusion, renal pathology in GSDI is characterized by progressive tubular dysfunction and the development of polycystic kidneys that probably leads to the development of irreversible renal failure in the late stages. Systematic observations of cyst development by kidney imaging should improve the evaluation of the disease's progression, independently of biochemical markers.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27436577 DOI: 10.1093/hmg/ddw224
Source DB: PubMed Journal: Hum Mol Genet ISSN: 0964-6906 Impact factor: 6.150